야마토릴게임 87.req598.top 바로가기 한게임바둑이게임, 잭팟게임

무료바다이야기 11.req598.top 소액 슬롯 추천

메타슬롯 22.req598.top 황금성게임다운로드

슬롯머신 이기는 방법 7.req598.top 빠친코게임

슬롯릴게임 19.req598.top 카지노릴게임

오리지날 야마토 90.req598.top 오리지널황금성

바다신2 영상 45.req598.top 야마토게임공략방법

해적게임 9.req598.top 바다이야기 사이트 먹튀

바다이야기무료체험 73.req598.top 무료야마토

슬롯머신 판매 중고 14.req598.top 황금성검증

바다이야기 예시 종료 57.req598.top 바다이야기 꽁머니

릴게임먹튀검증 방법 바다이야기무료 릴게임모바일 오션파라 다이스다운로드 온라인 황금성 바다이야기기계 무료충전 바다이야기 오리지날황금성9게임 무료게임다운로드 바다이야기 게임 방법 강원랜드 슬롯머신 잭팟 바다이야기pc버전다운 다빈치릴게임다운로드 바다이야기기계 다빈치게임다운로드 오션파라 다이스예시 슬롯 추천 디시 중고게임기매매 무료 바다이야기 슬롯머신게임 오션파라다이스3 바다이야기게임다운 알라딘게임공략법 야마토게임기 카지노 슬롯머신 규칙 릴예시게임 바다이야기 먹튀 돈 받기 황금성 무료머니 황금성3하는곳 황금성pc버전 오리지날야마토2게임 황금성오리지널 슬롯 하이클래스릴게임 골드몽먹튀 바다이야기 예시 무료인터넷게임 프라그마틱 무료 손오공릴게임예시 강원랜드 슬롯머신 가격 신천지게임하는곳 바다시즌7게임 신천지게임하는방법 슬롯 추천 디시 슬롯머신 777 무료백경 마이크로 슬롯 무료체험 릴게임판매 릴게임5만릴게임사이다 황금성게임장주소 알라딘설명 황금성게임장 무료충전야마토 슬롯머신 사이트 릴황금성 손오공 온라인 게임 우주전함 야마토 먹튀 pc야마토 릴게임 코리아 무료슬롯 얌얌 릴게임황금성 야마토게임다운 오션파라 다이스하는방법 야마토 빠칭코 황금성 슬롯 바다이야기 배당 바다이야기 예시 야마토3게임다운로드후기 체리 마스터 pc 용 오징어릴게임 잭팟게임 오락실슬롯머신 황금성어플 바다이야기노무현 야마토3게임다운로드후기 무료 슬롯 메타 슬롯릴게임 슬롯 머신 제작 무료백경 무료황금성 야마토사이트 오션슬롯먹튀 릴게임갓 황금성예시 슬롯머신 코딩 무료슬롯머신 황금성 릴게임 슬롯머신 종류 파칭코게임 신규슬롯사이트 체리마스터 어플 인터넷오션게임 알라딘 야마토게임사이트 알라딘 게임 다운 릴게임정글북 오락실게임 파라다이스 오션파라다이스예시 알라딘릴게임 바다이야기고래출현 파칭코게임다운로드 슬롯사이트 순위 바다이야기모바일 빠칭코 슬롯머신 온라인 황금성 손오공릴게임예시 황금성게임예시 온라인야마토2 바다이야기게임하는방법 릴게임백경 온라인 릴게임 사이트 바다이야기고래 바다슬롯 먹튀 오션파라 다이스예시 슬롯추천 바다이야기게임동영상 모바일오션파라다이스7 온라인 야마토 게임 강원랜드 잭팟 후기 슬롯머신 알고리즘 인터넷손오공게임 바다이야기모바일 오리지날황금성9게임 황금성2 프라그마틱 슬롯 무료 This article was released as Pharm Edaily Premium Content on September 21, 2025, at 2:18 PM.


[Shin-Min Joon, Edaily Reporter] On the 19th shares of Korean biopharmaceutical companies Olix and Hanmi Pharmaceutical both developing new drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) posted notable gains.
The surge was driven by optimism surPOSCO 주식
rounding the MASH market after global pharma giant Roche announced plans to acquire a MASH drug developer for approximately 5 trillion won. Additionally Ildong Pharmaceutical’s stock rose after a prev온라인 릴게임 정보
iously paywalled article from Pharmedaily regarding its obesity drug trial was made publicly available.



Olix stock trend on Sep 19. (Image=MP Doctor)
시간외거래



Roche to Acquire MASH Drug Developer for 5 Trillion Won

According to KG Zeroin’s MP DOCTOR (formerly Market Point), shares of Olix rose 1덕양산업 주식
8.46% on the day to 100,100 won. The surge followed news that Roche will acquire 89Bio, a U.S.-based MASH drug developer, for up to $3.5 billion (approximately 5 trillion won), with the deal expected 동양기전 주식
to close in Q4 of this year. After the acquisition, 89Bio will be integrated into Roche’s pharmaceutical division.
89Bio is currently conducting Phase 3 trials for its MASH drug candidate, pegozafermin. MASH is a chronic liver disease associated with obesity and metabolic disorders, potentially progressing to fibrosis, cirrhosis, and liver-related mortality. In 2023, 89Bio’s Phase 2b trial showed promising results in fibrosis improvement. The company is expected to release Phase 3 results in the first half of 2027.
Olix previously licensed its own MASH and obesity treatment candidate, OLX702A, to Eli Lilly in February for $630 million (approx. 911.7 billion won at the time). OLX702A is based on promising genetic targets identified through genome-wide association studies (GWAS), a method for finding disease-related genes by analyzing genomic variations in large populations.
Preclinical studies demonstrated that OLX702A not only showed efficacy in MASH and liver fibrosis, but also in other cardiovascular and metabolic diseases. Currently, a Phase 1 trial is ongoing in Australia, with the Clinical Study Report (CSR) expected in the first half of next year.
In addition to its MASH drug, Olix is also developing OLX301A for wet age-related macular degeneration and OLX104C for male-pattern hair loss. OLX301A is undergoing Phase 1 trials, with a CSR expected within the year. OLX104C completed its Phase 1a trial in January.
An Olix representative stated, “Roche’s acquisition of 89Bio has increased expectations for the MASH treatment market.”
Hanmi Pharmaceutical’s Triple Agonist Draws Attention
Shares of Hanmi Pharmaceutical also jumped 8.42% to 360,500 won. The rally appears to be driven by investor optimism over the company’s MASH drug pipeline. Hanmi currently has two MASH drug candidates under development. One of them, efocipegtrutide, is in Phase 2b trials in both Korea and the United States.
Efocipegtrutide is a long-acting triple agonist that targets glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), enhanced through Hanmi’s LAPSCOVERY platform. It has received Fast Track designation from the U.S. Food and Drug Administration (FDA) based on promising results in preclinical and early-phase trials.
Hanmi also out licensed epinopegdutide to Merck (MSD) in 2020, which is now in Phase 2 trials. Results are expected by year end. Epinopegdutide is a long acting dual agonist targeting GLP-1 and glucagon receptors.
With obesity and diabetes on the rise, the global MASH drug market is expected to expand. Market research firm DataM Intelligence forecasts that the MASH treatment market will grow from $7.8 billion (approx. 11 trillion won) in 2024 to $31.8 billion (approx. 44 trillion won) by 2033.
A Hanmi spokesperson said, “Hanmi is exploring innovative drug development across various therapeutic areas, not limited to specific diseases, and expanding its pipeline accordingly.”
Ildong’s Oral Obesity Drug Raises Hopes
Ildong Pharmaceutical shares rose 7.90% to 30,050 won, driven by anticipation over the upcoming topline results of its Phase 1 trial for the oral obesity drug ID110521156. Among Korean companies Ildong is leading in the clinical development of oral obesity drugs. Interim results have already shown competitive weight loss efficacy compared to global players.
A Pharmedaily article released on the day stated that the key lies in high dose data though even low doses have already proven effective. The article suggested that global benchmark results may be attainable.
ID110521156 achieved an average weight loss of 6.9% after four weeks in its Phase 1 interim results. The drug outperformed rivals such as Roche and Viking Therapeutics across both low and high dose groups.
Unlike injectable GLP-1 peptide drugs like Wegovy or Mounjaro ID110521156 is a small molecule GLP-1 agonist enabling better gastrointestinal absorption and higher success potential as an oral formulation.
The drug also showed only mild gastrointestinal side effects. In comparison Viking Therapeutics had a treatment discontinuation rate of 20% due to adverse effects. Ildong is expected to present topline data from the trial during a company presentation (NDR) for institutional investors on the 29th.
Ildong stated in a recent disclosure “We will hold an investor presentation on the 29th for institutional investors and analysts to enhance understanding and boost corporate value” adding “Topline results from the Phase 1 trial of ID110521156 will be revealed during the session.”
신민준 (adonis@edaily.co.kr)